Veppanu

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerFunction

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Veppanu

RRigel Pharmaceuticals

Phase 2

52

Adenocard

Astellas

Preclinical

23

Vfend

PPrism Pharmaceuticals

Preclinical

—4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

15

Tianeptine

Pfizer

Preclinical

16

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

17

Naltrexone/bupropion

Novo Nordisk

Preclinical

18

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

19

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

110

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer5 trials

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Active, not recruiting·Pfizer·Phase 1·NCT05463952·6 enrolled

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Active, not recruiting·Pfizer·Phase 3·NCT05909397·59 enrolled

TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY C (ARV-471 IN COMBINATION WITH SAMURACICLIB)

Terminated·Pfizer·Preclinical·NCT06125522·11 enrolled

Show 2 more trials

AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER

Active, not recruiting·Pfizer·Preclinical·NCT06206837·71 enrolled

A Phase 1/2, Open Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer, Who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting

Completed·AArvinas Estrogen Receptor, Inc.·Preclinical·NCT04072952·219 enrolled

Infusion1 trial

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

Completed·Pfizer·Phase 1·NCT06911788·10 enrolled

CAR1 trial

A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants

Completed·Pfizer·Phase 1·NCT06005688·12 enrolled

Midazolam1 trial

A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

Completed·Pfizer·Phase 1·NCT06256510·15 enrolled

ESS1 trial

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Completed·Pfizer·Phase 1·NCT06275841·12 enrolled

2 more indications

Adult1 trial

A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

Completed·Pfizer·Phase 1·NCT05538312·12 enrolled

Function1 trial

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

Not yet recruiting·Pfizer·Phase 1·NCT07231991·24 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News